Xeris Biopharma Holdings Inc (XERS) News

Form 3 - Initial statement of beneficial ownership of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to...

Form 8-K - Current report

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented...

Xeris to Participate in Upcoming Investor Conferences

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide...

Form 8-K - Current report

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million Year-end 2024 cash position expected...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and...